Literature DB >> 18494064

Is infliximab safe to use while breastfeeding?

Joel-Z Stengel1, Hays-L Arnold.   

Abstract

Inflammatory bowel disease (IBD) often affects women around the age of conception and pregnancy. Most drugs used to treat IBD are safe in pregnancy, but physicians must consider the clinical implications of certain treatment regimens in young, fertile females. We report an informative case of a pregnant patient with IBD who underwent treatment with infliximab during her pregnancy and while nursing her infant. Serum and breast milk infliximab levels were monitored throughout this time period. This case report suggests that targeted monoclonal antibodies and other biologic agents can be used with caution in pregnant and breastfeeding patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18494064      PMCID: PMC2712180          DOI: 10.3748/wjg.14.3085

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  13 in total

Review 1.  Inflammatory bowel disease and pregnancy: a review.

Authors:  E S Jospe; M A Peppercorn
Journal:  Dig Dis       Date:  1999       Impact factor: 2.404

Review 2.  Placental transport of immunoglobulin G.

Authors:  Neil E Simister
Journal:  Vaccine       Date:  2003-07-28       Impact factor: 3.641

Review 3.  Pregnancy and nursing in inflammatory bowel disease.

Authors:  Sonia Friedman; Miguel D Regueiro
Journal:  Gastroenterol Clin North Am       Date:  2002-03       Impact factor: 3.806

4.  [Term pregnancy in a patient with Crohn's disease under treatment with adalimumab].

Authors:  D Sánchez Muñoz; E Hoyas Pablos; M Ramírez Martín Del Campo; D Núñez Hospital; P Guerrero Jiménez
Journal:  Gastroenterol Hepatol       Date:  2005 Aug-Sep       Impact factor: 2.102

5.  Adalimumab use in pregnancy.

Authors:  L Vesga; J P Terdiman; U Mahadevan
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

6.  Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn's disease.

Authors:  A Tursi
Journal:  Dig Liver Dis       Date:  2006-03-23       Impact factor: 4.088

Review 7.  Safety of infliximab and other biologic agents in the inflammatory bowel diseases.

Authors:  Jagadeshwar G Reddy; Edward V Loftus
Journal:  Gastroenterol Clin North Am       Date:  2006-12       Impact factor: 3.806

8.  Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anti-cytokine treatment for rheumatoid arthritis.

Authors:  E S Sills; M Perloe; M J Tucker; C R Kaplan; G D Palermo
Journal:  Am J Reprod Immunol       Date:  2001-11       Impact factor: 3.886

9.  Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn.

Authors:  Eric A Vasiliauskas; Joseph A Church; Neil Silverman; Mary Barry; Stephan R Targan; Marla C Dubinsky
Journal:  Clin Gastroenterol Hepatol       Date:  2006-10       Impact factor: 11.382

10.  Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.

Authors:  Jeffry A Katz; Christian Antoni; Gregory F Keenan; Deirdre E Smith; Stephen J Jacobs; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2004-12       Impact factor: 10.864

View more
  13 in total

Review 1.  Behçet's syndrome in pregnancy.

Authors:  Marcus Martineau; Dorian O Haskard; Catherine Nelson-Piercy
Journal:  Obstet Med       Date:  2010-03-04

Review 2.  The management of rheumatic diseases in pregnancy.

Authors:  K Mitchell; M Kaul; Megan E B Clowse
Journal:  Scand J Rheumatol       Date:  2010-03       Impact factor: 3.641

Review 3.  Inflammatory bowel disease and pregnancy: evidence, uncertainty and patient decision-making.

Authors:  Flavio M Habal; Varun Kapila
Journal:  Can J Gastroenterol       Date:  2009-01       Impact factor: 3.522

4.  Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding.

Authors:  Harish Raja; Eric L Matteson; Clement J Michet; Justine R Smith; Jose S Pulido
Journal:  Transl Vis Sci Technol       Date:  2012-09-21       Impact factor: 3.283

5.  The use of anti-TNFα medications for rheumatologic disease in pregnancy.

Authors:  Megan Eb Clowse
Journal:  Int J Womens Health       Date:  2010-08-09

Review 6.  Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.

Authors:  Renée M Marchioni; Gary R Lichtenstein
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

Review 7.  Management of Inflammatory Bowel Disease During Pregnancy.

Authors:  Ariella Bar-Gil Shitrit; Sorina Grisaru-Granovsky; Ami Ben Ya'acov; Eran Goldin
Journal:  Dig Dis Sci       Date:  2016-04-11       Impact factor: 3.199

Review 8.  Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease.

Authors:  Frank Hoentjen; Ad A van Bodegraven
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742

Review 9.  From conception to delivery: managing the pregnant inflammatory bowel disease patient.

Authors:  Vivian W Huang; Flavio M Habal
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

Review 10.  Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding.

Authors:  Patricia Shu Kurizky; Clarissa de Castro Ferreira; Lucas Souza Carmo Nogueira; Licia Maria Henrique da Mota
Journal:  An Bras Dermatol       Date:  2015 May-Jun       Impact factor: 1.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.